Jamieson Wellness Inc. President and CEO Mark Hornick to Retire

Mike Pilato appointed President and CEO effective June 1, 2021

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX:JWEL) announced today that the Company's President and CEO Mark Hornick has decided to retire, after leading Jamieson Wellness through seven years of unprecedented growth. Jamieson Canada President Mike Pilato will advance to the role of President and CEO, effective June 1, 2021.

"I am thankful to Mark for his skillful leadership building our global presence and entrenching Jamieson as one of Canada's most trusted brands," said David Williams, Chair of the Board of Directors at Jamieson Wellness. "During his tenure, Mark restructured the organization behind a new vision, mission, and values, and with the support of a new leadership team, implemented a rapid growth strategy, doubling the company's topline revenue. The Board of Directors and I wish Mark the very best in his retirement and as we look to the future, we are confident that Mike is the right leader to take Jamieson to the next level."

"It has been my absolute honour to lead this company for the past seven years," said Mr. Hornick. "Our business has never been stronger, supported by a powerful brand, engaging culture and the deep commitment of our employees. The momentum we have driven over the past few years is still building, reinforcing that we have the right strategy in place to meet our long-term objectives. Mike is highly experienced with a proven track record of excellence and shared vision of improving the world's health and wellness. Over the next few months, Mike and I will work together to complete what has been an ongoing leadership transition."

"Jamieson Wellness is a highly respected global company with an amazing, dedicated team and an iconic brand that consumers around the world trust to support their health and wellness needs," said Mr. Pilato. "We have honed the company's long-term strategy over the past two years, prioritizing international growth opportunities, especially in China, along with fueling our organic growth in Canada. I am committed to building on this strategy and ensuring a seamless transition. I thank Mark and the Board of Directors for their support and confidence and look forward to working closely with the entire Jamieson team to continue driving sustainable growth and market leadership expansion."

Mr. Pilato joined Jamieson Wellness in 2018 as President of the Company's Specialty Brands division and was promoted to President, Jamieson Canada, in February 2020. Prior to Jamieson, Mr. Pilato held multiple leadership positions in the CPG space, culminating with serving as General Manager and President of The Clorox Company of Canada. During his tenure he led the organization to four years of record growth across multiple categories including household products, natural health and personal care.

About Jamieson Wellness Inc.

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. Jamieson Wellness manufactures and markets sports nutrition products and specialty supplements under its Progressive, Precision and Iron Vegan brands. The Company also markets Smart Solutions by Lorna Vanderhaeghe, the #1 women's natural health focused brand in Canada. For more information please visit jamiesonwellness.com.

Forward-Looking Information

This press release may contain forward-looking information within the meaning of applicable securities legislation. Such information includes, but is not limited to, statements related to the Company's future plans, goals, strategies, intentions, beliefs, objectives, economic performance or expectations. Words such as "expect", "anticipate", "intend", "may", "will", "estimate" and variations of such words and similar expressions are intended to identify such forward-looking information. This information reflects the Company's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the factors discussed under "Risk Factors" in the Company's Annual Information Form dated March 27, 2020 and under the "Risk Factors" section in the Company's MD&A filed February 25, 2021. This information is based on the Company's reasonable assumptions and beliefs in light of the information currently available to it and the statements are made as of the date of this press release. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law or regulatory authority.

The Company cautions that the list of risk factors and uncertainties is not exhaustive and other factors could also adversely affect the Company's results. Readers are urged to consider the risks, uncertainties and assumptions associated with these statements carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. See "Forward-looking Information" and "Risk Factors" within the Company's MD&A for a discussion of the uncertainties, risks and assumptions associated with these statements.

Investor and Media Contact:
Ruth Winker
Jamieson Wellness
416-705-5437
rwinker@jamiesonlabs.com

News Provided by Business Wire via QuoteMedia

The Conversation (0)
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

5 Best-performing Canadian Pharma Stocks in 2026

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover, develop and commercialize major innovations amid an increasingly competitive global landscape. Rising technologies such as artificial... Keep Reading...
Stethoscope rests on stacks of US money over a bright blue background.

Eli Lilly to Buy Psychedelics Firm AtaiBeckley for US$2.8 Billion

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is pushing further into the psychedelic drug market with a US$2.8 billion buyout of clinical-stage developer AtaiBeckley (NASDAQ:ATAI). The crown jewel of the deal is BPL-003, a clinic-administered nasal spray derived from dimethyltryptamine... Keep Reading...
BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer

BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer

Sunnybrook's Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell's pivotal Phase 3 clinical trial in metastatic breast cancerBriaCell Phase 3 trial featured in Nature Medicine as one of "Eleven clinical trials that will shape medicine in 2026" briacell... Keep Reading...
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT

Arrangement with FUJIFILM Biotechnologies California provides manufacturing capacity for the remainder of BriaCell's pivotal Phase 3 study and commercial scalability potential Bria-IMT is currently being evaluated in Bria-Cell's ongoing pivotal Phase 3 study in metastatic breast cancer briacell... Keep Reading...
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT

Charles River Associates (CRA) to evaluate epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer in the USKaleio to support brand strategies and customized commercial-readiness solutionsBria-IMT is currently being evaluated in... Keep Reading...
Syringes with measurement markings overlaid with a fluctuating blue and white line graph.

Zymeworks Expands into Respiratory Market with Theravance Buyout

Oncology-focused drugmaker Zymeworks (NASDAQ:ZYME) has agreed to acquire Theravance Biopharma (NASDAQ:TBPH) for US$929 million in cash, expanding its portfolio into the respiratory segment.The acquisition delivers Zymeworks a 35 percent US net profit share in Yupelri, the first and only... Keep Reading...

Interactive Chart

Latest Press Releases

Related News